Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience

Genitourinary Cancer

Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases

Prostate Cancer Prostatic Dis

Mian Z, Gianduzzo T, Kua B, Yaxley J

doi: 10.1038/s41391-026-01148-x

Multiple Myeloma (MM)

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Blood Cancer J

Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD Jr, Lee HC

doi: 10.1038/s41408-025-01414-6

Head and Neck Cancer

Outcomes of different treatment patterns for adenoid cystic carcinoma of the anterior craniofacial area: A multi-institutional study on 578 patients

Eur J Cancer

Ferrari M, Schiavo G, Gaudioso P, Su S, Orlandi E, Mattavelli D, Turri-Zanoni M, Lombardi D, Verillaud B, Anile G, Arosio AD, Borsetto D, Chatelet F, Creber N, DeMonte F, Deretti A, Ferrarotto R, Finozzi F, Ghi MG, Gravante G, Khalaf M, Krengli M, Lambertoni A, Lechner M, Locati LD, Lund VJ, Phan J, Rampinelli V, Raza S, Ruaro A, Sharma R, Taboni S, Testa G, Tomasoni M, Vinciguerra A, Zanoletti E, Bossi P, Moya-Plana A, Herman P, Battaglia P, Bignami M, Castelnuovo P, Vischioni B, Piazza C, Nicolai P, Hanna EY

doi: 10.1016/j.ejca.2026.116680

Lymphoma

Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience

Br J Haematol

Gavriatopoulou M, Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Manganas S, Theodorakakou F, Solia I, Eleutherakis-Papaiakovou E, Katsadouros I, Boutsikos P, Fotiou D, Migkou M, Kanellias N, Terpos E, Kastritis E, Dimopoulos MA

doi: 10.1111/bjh.70693

Sarcoma

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group

Eur J Cancer

Kalfala E, Meurgey A, Hénon C, Brahmi M, Toulmonde M, Boudou-Rouquette P, Bompas E, Penel N, Firmin N, Duffaud F, Desmoulins I, Ducoulombier A, Cancel M, Watson S, Khettab M, Darbas T, Kieffer A, Guillemet C, Gantzer J, Perrin C, Genevois AL, Orbach D, Chabaud S, Blay JY, Dufresne A

doi: 10.1016/j.ejca.2026.116590

Leukemia

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience

Br J Haematol

Chan WY, Al-Yousuf H, Lam HPJ, Leong S, Zheng J, Burt R, Wilson AJ, Xu K, Stringaris K, Alimam S, Raj K, Gupta R, Kottaridis P, Tailor A, Burgoyne R, Mansour MR, Khwaja A, Sellar R, Payne EM, O'Nions J

doi: 10.1111/bjh.70676

Multiple Myeloma (MM)

Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database

Leuk Lymphoma

Nieto MJ, Shih YH, Fang J, Qiu Y, Gentili C, Hernandez Rivera G

doi: 10.1080/10428194.2026.2702128

Non-Malignant Blood Disorders

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study

Br J Haematol

Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H

doi: 10.1111/bjh.70531

Breast Cancer

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer

J Natl Cancer Inst

Nader-Marta G, Zheng Y, Rosenberg SM, Dibble KE, Mayer EL, Poorvu PD, Ruddy KJ, Guzman-Arocho YD, Collins LC, Peppercorn J, Schapira L, Valenza C, Borges VF, Tayob N, Come SE, Warner E, Polyak K, Winer EP, Partridge AH

doi: 10.1093/jnci/djag152

Related content

Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Outcomes of different treatment patterns for adenoid cystic carcinoma of the anterior craniofacial area: A multi-institutional study on 578 patients

Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience

Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer